AJANTA PHARMA | ELDER PHARMA | AJANTA PHARMA/ ELDER PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 24.7 | -0.2 | - | View Chart |
P/BV | x | 6.9 | 0.1 | 6,797.8% | View Chart |
Dividend Yield | % | 0.5 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-19 |
ELDER PHARMA Jun-14 |
AJANTA PHARMA/ ELDER PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,422 | 380 | 374.2% | |
Low | Rs | 898 | 188 | 477.4% | |
Sales per share (Unadj.) | Rs | 233.5 | 491.2 | 47.5% | |
Earnings per share (Unadj.) | Rs | 44.0 | -3.2 | -1,381.8% | |
Cash flow per share (Unadj.) | Rs | 52.2 | 14.4 | 362.0% | |
Dividends per share (Unadj.) | Rs | 9.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 255.1 | 376.5 | 67.7% | |
Shares outstanding (eoy) | m | 88.02 | 20.54 | 428.5% | |
Bonus/Rights/Conversions | BB | - | - | ||
Price / Sales ratio | x | 5.0 | 0.6 | 859.0% | |
Avg P/E ratio | x | 26.4 | -89.3 | -29.6% | |
P/CF ratio (eoy) | x | 22.2 | 19.7 | 112.8% | |
Price / Book Value ratio | x | 4.5 | 0.8 | 602.8% | |
Dividend payout | % | 20.5 | 0 | - | |
Avg Mkt Cap | Rs m | 102,081 | 5,833 | 1,750.0% | |
No. of employees | `000 | 6.8 | NA | - | |
Total wages/salary | Rs m | 4,307 | 2,179 | 197.7% | |
Avg. sales/employee | Rs Th | 3,022.6 | NM | - | |
Avg. wages/employee | Rs Th | 633.4 | NM | - | |
Avg. net profit/employee | Rs Th | 569.1 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,554 | 10,089 | 203.7% | |
Other income | Rs m | 211 | 257 | 82.2% | |
Total revenues | Rs m | 20,765 | 10,346 | 200.7% | |
Gross profit | Rs m | 5,664 | -792 | -715.3% | |
Depreciation | Rs m | 721 | 361 | 199.5% | |
Interest | Rs m | 12 | 2,756 | 0.4% | |
Profit before tax | Rs m | 5,143 | -3,653 | -140.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 3,713 | 0.0% | |
Tax | Rs m | 1,273 | 125 | 1,017.2% | |
Profit after tax | Rs m | 3,870 | -65 | -5,921.5% | |
Gross profit margin | % | 27.6 | -7.8 | -351.1% | |
Effective tax rate | % | 24.8 | -3.4 | -722.5% | |
Net profit margin | % | 18.8 | -0.6 | -2,906.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,812 | 9,240 | 127.8% | |
Current liabilities | Rs m | 3,776 | 9,998 | 37.8% | |
Net working cap to sales | % | 39.1 | -7.5 | -520.6% | |
Current ratio | x | 3.1 | 0.9 | 338.4% | |
Inventory Days | Days | 77 | 46 | 167.1% | |
Debtors Days | Days | 82 | 60 | 136.1% | |
Net fixed assets | Rs m | 14,398 | 10,124 | 142.2% | |
Share capital | Rs m | 175 | 206 | 85.3% | |
"Free" reserves | Rs m | 22,277 | 5,582 | 399.1% | |
Net worth | Rs m | 22,452 | 7,734 | 290.3% | |
Long term debt | Rs m | 7 | 4,889 | 0.1% | |
Total assets | Rs m | 26,962 | 22,882 | 117.8% | |
Interest coverage | x | 444.3 | -0.3 | -136,596.5% | |
Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.4 | 172.9% | |
Return on assets | % | 14.4 | 11.8 | 122.4% | |
Return on equity | % | 17.2 | -0.8 | -2,039.6% | |
Return on capital | % | 23.0 | 22.3 | 102.9% | |
Exports to sales | % | 0 | 3.0 | 0.0% | |
Imports to sales | % | 0 | 0.4 | 0.0% | |
Exports (fob) | Rs m | NA | 307 | 0.0% | |
Imports (cif) | Rs m | NA | 43 | 0.0% | |
Fx inflow | Rs m | 10,682 | 307 | 3,483.9% | |
Fx outflow | Rs m | 2,102 | 125 | 1,677.5% | |
Net fx | Rs m | 8,580 | 181 | 4,732.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,748 | 11,754 | 31.9% | |
From Investments | Rs m | -2,228 | -561 | 397.5% | |
From Financial Activity | Rs m | -1,475 | -6,762 | 21.8% | |
Net Cashflow | Rs m | 45 | 4,432 | 1.0% |
Indian Promoters | % | 73.8 | 39.6 | 186.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.6 | 7.5 | 20.7% | |
FIIs | % | 7.6 | 16.8 | 45.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.0 | 36.1 | 47.1% | |
Shareholders | 20,968 | 16,479 | 127.2% | ||
Pledged promoter(s) holding | % | 4.4 | 77.6 | 5.7% |
Compare AJANTA PHARMA With: ALEMBIC SUN PHARMA IPCA LABS SUVEN LIFE SCIENCES DR. REDDYS LAB
Compare AJANTA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this video, I'll show you how to allocate your capital as a day trader.
More